All In MedTech

FDA Clearance Tracker · P240042

Tendyne Transcatheter Mitral Valve System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this decision)Source: openFDAMethods & limitations

PMABreakthrough

Decided

May 23, 2025

Approved

Time to decision

177 days

Received Nov 27, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240042
Device name
Tendyne Transcatheter Mitral Valve System
Applicant location
St. Paul, MN
Received
Nov 27, 2024
Decided
May 23, 2025
Decision
Approved
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NPU

FDA's approval statement

As written in FDA's record.

Approval for the Tendyne Transcatheter Mitral Valve System. This device is indicated for the treatment of symptomatic severe mitral valve dysfunction (moderate-to-severe or severe mitral regurgitation [MR], severe mitral stenosis [MS], or moderate MR with moderate or greater MS) associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair by a multidisciplinary heart team.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NPU. The earliest in FDA's data is P140031-S162, decided May 23, 2024.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.